Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Aggressive CT or PET/CT surveillance protocols confer significant risk of radiation-induced cancer in patients being monitored for metastasis from primary choroidal melanoma, California-based…
Robert Komitor, an attorney at Levy Philips & Konigsberg, LLP, discusses the best way for mesothelioma patients to receive compensation. Asbestos exposure is the only known and well…
NEW YORK (Reuters Health) – In HIV patients with anal intraepithelial neoplasia (AIN), infrared coagulation (IRC) helps avoid progression to squamous cell carcinoma (SCC), Spanish doctors say. “High-grade…
NEW YORK (Reuters Health) – Men with isolated high-grade prostatic intraepithelial neoplasia (HGPIN) are at relatively high risk for developing prostate cancer, and treatment with toremifene does not…
NEW YORK (Reuters Health) – Among patients undergoing liver transplantation for hepatocellular carcinoma, the risk of recurrence is lower when immunosuppression is based on sirolimus rather than calcineurin…
NEW YORK (Reuters Health) – A French team reports some advantages with robot-assisted compared to conventional laparoscopic radical prostatectomy performed via an extraperitoneal approach. “This study did not…
Lee Krug, MD, discusses the current state of mesothelioma treatments as well as new therapies in development. He mentions the possibilities of clinical trials for angiogenesis inhibitors and anti-VEGF antibodies for mesothelioma…
More than 2700 people lost their lives during the terrorist attacks on the World Trade Center in New York City. The attack also exposed hundreds of thousands of…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to FOLFOX chemotherapy does not improve outcomes in patients with stage II-III colon cancer, according to a…
ZURICH (Reuters) – Swiss pharma group Roche’s drug Perjeta (pertuzumab) significantly extended the lives of women with HER2-positive breast cancer compared to a placebo, according to new data…
